INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RBV IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS

E.J. Gane,1,2,3,4,5,6,7,8,9,10,11 P. Pockros,6,7,8,9,10,11 S. Zeuzem,1,2,3,4,5,6,7,8,9,10,11 P. Marcellin,1,2,3,4,5,6,7,8,9,10,11 A. Shikhman,1,2,3,4,5,6,7,8,9,10,11 C. Bernards,6,7,8,9,10,11 E. Yetzer,1,2,3,4,5,6,7,8,9,10,11 N.S. Shults,1,2,3,4,5,6,7,8,9,10,11 X. Teng,1,2,3,4,5,6,7,8,9,10,11 I. Nájera,1,2,3,4,5,6,7,8,9,10,11 A. Bertasso,1,2,3,4,5,6,7,8,9,10,11 J. Hammond,1,2,3,4,5,6,7,8,9,10,11 S. Stanciu,1,2,3,4,5,6,7,8,9,10,11 A. Domanovsky,1,2,3,4,5,6,7,8,9,10,11 C. C. Cheung,1,2,3,4,5,6,7,8,9,10,11 L. S. Lin,1,2,3,4,5,6,7,8,9,10,11 C. V. Tomajko,1,2,3,4,5,6,7,8,9,10,11 M. Stange,1,2,3,4,5,6,7,8,9,10,11 N. B. Dussap,1,2,3,4,5,6,7,8,9,10,11 P. D. Fanning,1,2,3,4,5,6,7,8,9,10,11 F. P. Schindler,1,2,3,4,5,6,7,8,9,10,11 R. Z. Koziol,1,2,3,4,5,6,7,8,9,10,11 M. G. L. Lel有什么内容，因为没有提供。